REGENXBIO, Inc. (RGNX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$6.68-6.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge REGENXBIO, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	32.87M
EPS	—	-0.93
Annual ending 2026-12-31
Revenue	—	161M
EPS	—	-3.364
Annual ending 2027-12-31
Revenue	—	198.48M
EPS	—	-2.899

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash to fund operations into early 2027	Regenxbio has a $150 million cash balance to fund operations into 2027.	Improving	cash balance falls below $100 million before early 2027	Cash and cash equivalents: $36.487M FY2026-Q2; GAAP. Published target: >= $150 million cash balance. Target period is not explicitly aligned with this observation. Source date unavailable36,487,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resolve FDA rejection of RGX-121 and GSK sublicense dispute	The company is working to resolve FDA and GSK regulatory issues.	Under Pressure	FDA rejection or GSK dispute unresolved past 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize and grow revenue after expected decline	A primary condition in REGENXBIO, Inc.'s published investment case. The stated target is Revenue decline less than 10% YoY by FY27.	Improving	Revenue decline exceeds 10% YoY in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.90

$-2.54 → $-2.90 · observed estimates

FY2027 revenue$0.20B

$0.25B → $0.20B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.54	$247,511,970	7 / 8
2026-07-25	$-2.54	$247,511,970	7 / 8
2026-07-26	$-2.54	$247,511,970	7 / 8
2026-07-27	$-2.54	$247,511,970	7 / 8
2026-07-28	$-2.84	$269,109,574	6 / 6
2026-07-29	$-2.84	$269,109,574	6 / 6
2026-07-30	$-2.84	$269,109,574	6 / 6
2026-07-31	$-2.84	$269,109,574	6 / 6
2026-08-01	$-2.84	$269,109,574	6 / 6
2026-08-02	$-2.54	$247,511,970	7 / 8
2026-08-03	$-2.54	$247,511,970	7 / 8
2026-08-04	$-2.54	$247,511,970	7 / 8
2026-08-05	$-2.54	$247,511,970	7 / 8
2026-08-06	$-2.54	$247,511,970	7 / 8
2026-08-08	$-2.54	$259,386,970	7 / 8
2026-08-09	$-2.58	$234,605,030	7 / 8
2026-08-10	$-2.84	$269,109,574	6 / 6
2026-08-12	$-2.84	$269,109,574	6 / 6
2026-08-13	$-2.31	$257,283,360	8 / 9
2026-08-14	$-2.84	$269,109,574	6 / 6
2026-08-15	$-2.84	$269,109,574	7 / 7
2026-08-16	$-2.84	$269,109,574	7 / 7
2026-08-17	$-2.84	$269,109,574	7 / 7
2026-08-18	$-2.84	$269,109,574	7 / 7
2026-08-19	$-2.84	$269,109,574	7 / 7
2026-08-20	$-2.26	$260,414,026	6 / 7
2026-08-21	$-2.26	$260,414,026	6 / 7
2026-08-22	$-2.26	$260,414,026	6 / 7
2026-08-23	$-2.26	$260,414,026	6 / 7
2026-08-24	$-2.26	$260,414,026	6 / 7
2026-08-25	$-2.91	$213,204,027	6 / 7
2026-08-26	$-2.91	$213,204,027	6 / 7
2026-08-27	$-2.91	$213,204,027	6 / 7
2026-08-28	$-2.91	$213,204,027	6 / 7
2026-08-29	$-2.91	$213,204,027	6 / 7
2026-08-30	$-2.91	$213,204,027	6 / 7
2026-08-31	$-2.91	$213,204,027	6 / 7
2026-09-01	$-2.91	$213,204,027	6 / 7
2026-09-02	$-2.91	$213,204,027	6 / 7
2026-09-03	$-2.91	$213,204,027	6 / 7
2026-09-04	$-2.91	$213,204,027	6 / 7
2026-09-05	$-2.91	$213,204,027	6 / 7
2026-09-06	$-2.91	$213,204,027	6 / 7
2026-09-07	$-2.91	$213,204,027	6 / 7
2026-09-08	$-2.91	$213,204,027	6 / 7
2026-09-09	$-2.91	$213,204,027	6 / 7
2026-09-10	$-2.91	$213,204,027	6 / 7
2026-09-11	$-2.91	$213,204,027	6 / 7
2026-09-12	$-2.91	$213,204,027	6 / 7
2026-09-13	$-2.91	$213,204,027	6 / 7
2026-09-14	$-2.91	$213,204,027	6 / 7
2026-09-15	$-2.91	$213,204,027	6 / 7
2026-09-16	$-2.91	$213,204,027	6 / 7
2026-09-17	$-2.91	$213,204,027	6 / 7
2026-09-18	$-2.91	$213,204,027	6 / 7
2026-09-19	$-2.91	$213,204,027	6 / 7
2026-09-20	$-2.91	$213,204,027	6 / 7
2026-09-21	$-2.91	$213,204,027	6 / 7
2026-09-22	$-2.91	$213,204,027	6 / 7
2026-09-23	$-2.91	$213,204,027	6 / 7
2026-09-24	$-2.91	$213,204,027	6 / 7
2026-09-25	$-2.91	$213,204,027	6 / 7
2026-09-26	$-2.91	$213,204,027	6 / 7
2026-09-27	$-2.91	$213,204,027	6 / 7
2026-09-28	$-2.91	$213,204,027	6 / 7
2026-09-29	$-2.91	$213,204,027	6 / 7
2026-09-30	$-2.91	$213,204,027	6 / 7
2026-10-01	$-2.91	$213,204,027	6 / 7
2026-10-02	$-2.91	$213,204,027	6 / 7
2026-10-03	$-2.91	$213,204,027	6 / 7
2026-10-04	$-2.91	$213,204,027	6 / 7
2026-10-05	$-2.91	$213,204,027	6 / 7
2026-10-06	$-2.90	$198,449,115	7 / 8
2026-10-07	$-2.90	$198,449,115	7 / 8
2026-10-08	$-2.90	$198,449,115	7 / 8
2026-10-09	$-2.90	$198,449,115	7 / 8
2026-10-10	$-2.90	$198,449,115	7 / 8
2026-10-11	$-2.90	$198,449,115	7 / 8
2026-10-12	$-2.90	$198,449,115	7 / 8
2026-10-13	$-2.90	$198,476,388	7 / 8
2026-10-14	$-2.90	$198,476,388	7 / 8
2026-10-15	$-2.90	$198,476,388	7 / 8
2026-10-16	$-2.90	$198,476,388	7 / 8
2026-10-17	$-2.90	$198,476,388	7 / 8
2026-10-18	$-2.90	$198,476,388	7 / 8
2026-10-19	$-2.90	$198,476,388	7 / 8
2026-10-20	$-2.90	$198,476,388	7 / 8
2026-10-21	$-2.90	$198,476,388	7 / 8
2026-10-22	$-2.90	$198,476,388	7 / 8
2026-10-23	$-2.90	$198,476,388	7 / 8
2026-10-24	$-2.90	$198,476,388	7 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	1
2026-06-01	10	1
2026-07-01	10	1
2026-08-01	10	2
2026-09-01	9	2
2026-10-01	10	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Mizuho SecuritiesOct 5

$22.00New observation · no comparable prior

$0$12.10$24.20

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash to fund operations into early 2027Cash and cash equivalents: $36.487M
Resolve FDA rejection of RGX-121 and GSK sublicense disputePublished status: Under Pressure
Stabilize and grow revenue after expected declineDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-64.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

REGENXBIO, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not a steady earnings compounder. The thesis is currently intact: RGX-202 has delivered progress and a large milestone, while the company remains loss-making overall and faces elevated risks.

What's priced into REGENXBIO, Inc.

The evidence describes RGNX as cheap versus peers, though the valuation model has low confidence and the expectations gap is negative. The priced-in assessment is marked justified, with no fragility gates triggered, but this does not remove the uncertainty around future clinical and financial results.

What the fundamentals likely do

Near term, reported revenue and net income can be volatile: second-quarter revenue included a $100 million milestone, and results shifted from a loss in the first quarter to a profit in the second. Management is advancing RGX-202, while sura-vec remains mixed ahead of anticipated pivotal data in Q4 2026; an earnings miss is a meaningful risk given erratic surprises. A CEO transition and pending legal and regulatory matters add uncertainty.

What REGENXBIO, Inc. hinges on

Over the next one to three years, the thesis hinges on continued RGX-202 clinical progress and the path toward a BLA submission, a regulatory filing for approval. Sura-vec data and resolution of legal and regulatory matters are also important, while guidance cuts or weaker employment data could weigh on the near-term business setting. Continued strength among healthcare peers may support sector momentum, but is not specific proof of RGNX’s progress.